0

Home > Drug Category > Antiepileptic Medication > Depakote and Equivalent

Depakote (Divalproex Sodium) Information

Depakote (divalproex sodium) is a widely prescribed anticonvulsant medication with a broad spectrum of clinical uses, including as an antiepileptic drug, a mood stabilizer, and a migraine prophylactic. It is indicated for the treatment of manic episodes associated with bipolar disorder, as well as for the prophylaxis of migraine headaches. In the context of epilepsy, Depakote is used for both monotherapy and adjunctive therapy for various seizure types, including complex partial seizures, simple and complex absence seizures (petit mal), and adjunctive treatment in patients with multiple seizure types that include absence seizures. The medication is available in various oral forms, including delayed-release (DR) tablets, extended-release (ER) tablets, and sprinkle capsules, which contain a stable coordination compound of valproic acid and sodium valproate.

The therapeutic mechanism of divalproex sodium is complex and not fully elucidated. However, its key actions are primarily related to increasing the concentration of gamma-aminobutyric acid (GABA) in the brain, which is the chief inhibitory neurotransmitter. By inhibiting the catabolism (breakdown) of GABA and potentially affecting its synthesis, Depakote increases GABA's inhibitory action, thereby suppressing the rapid, repetitive firing of neurons that causes seizures. Additionally, the drug is believed to exert its effects by blocking voltage-gated sodium channels and calcium channels, thereby further stabilizing neuronal membranes and reducing abnormal electrical activity in the central nervous system. This multi-action mechanism contributes to its efficacy across different neurological and psychiatric conditions. Dosing of Depakote is highly individualized and is guided by the patient's weight and condition, with therapeutic effects often monitored via plasma drug concentrations.

Depakote Side Effects

Depakote can cause a range of side effects, with many being common and usually mild, such as gastrointestinal distress, especially at the start of therapy. Common side effects often include nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, somnolence (sleepiness), tremor (shaking), and changes in appetite leading to weight gain or loss. Patients may also experience alopecia (hair loss), which is often reversible upon drug discontinuation.

However, divalproex sodium carries multiple Boxed Warnings from regulatory bodies, highlighting the potential for severe and life-threatening adverse reactions. These serious side effects require immediate attention:

• Fetal Harm/Teratogenicity (Boxed Warning): When taken during pregnancy, Depakote can cause major congenital malformations, most notably neural tube defects (NTDs) like spina bifida, and is associated with reduced IQ scores and an increased risk of autism spectrum disorders in children exposed in utero.

• Hepatotoxicity (Liver Damage) (Boxed Warning): Severe or fatal hepatic failure has been reported, typically within the first six months of treatment. The risk is significantly higher in children younger than two years old, particularly those on multiple anticonvulsants or with pre-existing metabolic disorders. Symptoms include malaise, weakness, lethargy, facial edema, anorexia, vomiting, and jaundice.

• Hyperammonemia (High Blood Ammonia): This can occur with or without concurrent lethargy or coma (encephalopathy) and is more likely when taken with topiramate. Symptoms may include confusion, vomiting, and unexplained tiredness.

• Pancreatitis (Boxed Warning): Life-threatening pancreatitis has occurred in both children and adults, developing at any time during treatment. Symptoms, such as severe abdominal pain spreading to the back, nausea, vomiting, and loss of appetite, require immediate discontinuation of the drug. • Suicidal Behaviour and Ideation: Like all antiepileptic drugs, Depakote increases the risk of suicidal thoughts or behaviour.

• Thrombocytopenia and Bleeding: Depakote can cause a decrease in blood platelet count (thrombocytopenia) and subsequent bleeding problems.

Depakote Precautions

Due to the significant risks associated with Depakote, several stringent precautions and monitoring requirements are necessary during therapy. Patients with known or suspected hepatic disease or significant hepatic dysfunction are contraindicated from using Depakote. Liver function tests (LFTs) must be performed before initiating therapy and monitored frequently, especially during the first six months. Patients should be instructed to report any signs of liver or pancreatic issues immediately. For women of childbearing potential, Depakote poses a significant teratogenic risk. Unless the drug is essential for managing her condition and other medications have failed, Depakote should not be administered to pregnant women. The FDA has mandated a specific risk category (Category D or X for migraine prophylaxis) and recommends enrollment in a pregnancy registry. Women of childbearing potential must use effective contraception and be fully counselled on the risks of fetal harm before and during treatment. The drug is contraindicated for migraine prophylaxis in pregnant women and women who are not using effective contraception. Patients should be continuously monitored for the emergence or worsening of depression, unusual changes in mood or behaviour, or the development of suicidal thoughts or behaviour. Caution is warranted in elderly patients, who may be more susceptible to somnolence, accidental injury, and nutritional changes. Patients with specific genetic conditions, such as known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase (POLG), are at a considerably increased risk of fatal hepatotoxicity and should generally avoid Depakote. Furthermore, Depakote is contraindicated in patients with a known or suspected Urea Cycle Disorder (UCD) due to the risk of fatal hyperammonemic encephalopathy. Abrupt discontinuation of Depakote should be avoided, as it can precipitate seizures and increase the risk of status epilepticus.

Do I need a prescription to order Depakote?

Yes, a prescription is required from your physician to order Depakote.